Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Eiger BioPharmaceuticals Inc. (EIGR) is expected to report for Q3 2023
2023-09-13 09:58:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sigma Lithium (NASDAQ: SGML ) stock is climbing higher on Wednesday after confirming it received strategic proposals . According to a news release, Sigma Lithium’...
2023-09-13 09:39:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Workhorse (NASDAQ: WKHS ) stock is on the rise Wednesday, thanks to a new update from the IRS concerning its electric vehicle (EV) manufacturer status. The IRS has appro...
2023-09-13 09:20:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial . According to a press release...
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta PR Newswire PALO ALTO, Calif. , Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focus...
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the...
2023-08-14 17:20:38 ET Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q2 GAAP EPS of -$0.47 misses by $0.08 . Revenue of $4.64M (+13.4% Y/Y) beats by $0.07M . Cash, cash equivalents, and short-term debt securities as of June 30, 2023 totaled...
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...